IAG Bio-Partnering Team to Attend BIO in Boston, USA
IAG, CEO, Dr. Olga Kubassova, and lead Bio-Partnering Analyst, Dr. Diana Roettger will be attending BIO 2018 in Boston, USA, from June 1-5. IAG partners with biotechnology and pharmaceutical companies and supports clinical research programs with its scientific, operational and technological expertise. IAG Bio-Partnering division is an independent investment division of IAG that works to build a diversified investment portfolio of innovative life science companies at various stages of clinical development.
The scope of discussions for this conference include:
– Development of clinical stage assets
– IP acquisition from the academic partners and biotech companies
– Investment partnerships
– Strategic collaborations
Given the increasing need for collaboration in therapy development, Dr. Kubassova and Dr. Roettger will introduce IAG’s technology-enabled, risk-sharing and mitigation partnerships, and targeted development strategies. To find out more about IAG Bio-Partnering services or to schedule a meeting during BIO 2018 please send an email to firstname.lastname@example.org
About BIO 2018
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. The key benefits of attending the 2018 BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries. To find out more information click here.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: email@example.com
Follow the Company: Linkedin